ID   Detroit 562
AC   CVCL_1171
SY   DETROIT 562; Detroit-562; Detroit562; DETROIT562; Det 562; Det. 562; Det562; D562
DR   BTO; BTO:0000834
DR   CLO; CLO_0002752
DR   EFO; EFO_0002170
DR   CLDB; cl1035
DR   CLDB; cl1036
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CCL-138
DR   ATCC; CRL-7919
DR   BCRC; 60119
DR   BCRJ; 0076
DR   BioGRID_ORCS_Cell_line; 686
DR   BioSample; SAMN03473286
DR   BioSample; SAMN10988307
DR   cancercelllines; CVCL_1171
DR   CCRID; 3101HUMTCHu231
DR   Cell_Model_Passport; SIDM00831
DR   ChEMBL-Cells; CHEMBL3308486
DR   ChEMBL-Targets; CHEMBL1075432
DR   CLS; 300399
DR   Cosmic; 686974
DR   Cosmic; 906837
DR   Cosmic; 921830
DR   Cosmic; 1017788
DR   Cosmic; 1006472
DR   Cosmic; 1041673
DR   Cosmic; 1339917
DR   Cosmic; 1752763
DR   Cosmic; 2043891
DR   Cosmic; 2296294
DR   Cosmic-CLP; 906837
DR   DepMap; ACH-000207
DR   ECACC; 87042205
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 906837
DR   GEO; GSM301580
DR   GEO; GSM827340
DR   GEO; GSM886977
DR   GEO; GSM888046
DR   GEO; GSM1374461
DR   GEO; GSM1374462
DR   GEO; GSM1643590
DR   GEO; GSM1669730
DR   IARC_TP53; 2327
DR   IGRhCellID; Detroit562
DR   IZSLER; BS TCL 16
DR   LiGeA; CCLE_046
DR   LINCS_LDP; LCL-1226
DR   PharmacoDB; Detroit562_288_2019
DR   PRIDE; PXD002486
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1171
DR   PubChem_Cell_line; CVCL_1171
DR   Wikidata; Q54831001
RX   DOI=10.1007/978-1-4757-1647-4_13;
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=77569;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=3518877;
RX   PubMed=5668122;
RX   PubMed=6220172;
RX   PubMed=6401685;
RX   PubMed=6500159;
RX   PubMed=6988327;
RX   PubMed=10760816;
RX   PubMed=12124801;
RX   PubMed=15197768;
RX   PubMed=18973137;
RX   PubMed=20215515;
RX   PubMed=21868764;
RX   PubMed=22460905;
RX   PubMed=24201445;
RX   PubMed=25275298;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=26754630;
RX   PubMed=27397505;
RX   PubMed=29156801;
RX   PubMed=29423072;
RX   PubMed=30877674;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Part of: OPC-22 oral and pharyngeal cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 88.5 +- 34.7 hours (PubMed=29423072).
CC   HLA typing: A*03,11; B*13 (PubMed=77569).
CC   HLA typing: A*26:01,30:01; B*13:02,55:01; C*01:02,06:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=25275298).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.82%; Native American=0%; East Asian, North=1.93%; East Asian, South=0%; South Asian=1.05%; European, North=61.34%; European, South=34.86% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-7919; true.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC; CLS; Cosmic-CLP; ECACC; IZSLER; PubMed=21868764; PubMed=25275298; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 15
ST   D19S433: 14
ST   D21S11: 28,30
ST   D2S1338: 25
ST   D3S1358: 15,16
ST   D5S818: 11,12
ST   D7S820: 8 (CLS)
ST   D7S820: 8,10 (ATCC; Cosmic-CLP; ECACC; IZSLER; PubMed=21868764; PubMed=25275298; PubMed=25877200)
ST   D8S1179: 13,14
ST   FGA: 21
ST   Penta D: 13
ST   Penta E: 13
ST   TH01: 8 (CLS)
ST   TH01: 8,9 (ATCC; Cosmic-CLP; ECACC; IZSLER; PubMed=21868764; PubMed=25275298; PubMed=25877200)
ST   TPOX: 8,10
ST   vWA: 16
DI   NCIt; C102872; Pharyngeal squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 46
//
RX   DOI=10.1007/978-1-4757-1647-4_13;
RA   Biedler J.L.;
RT   "Chromosome abnormalities in human tumor cells in culture.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975).
//
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994).
//
RX   PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x;
RA   Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.;
RT   "Tissue typing of cells in culture. III. HLA antigens of established
RT   human cell lines. Attempts at typing by the mixed hemadsorption
RT   technique.";
RL   Tissue Antigens 11:279-286(1978).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=5668122; DOI=10.3181/00379727-128-33119;
RA   Peterson W.D. Jr., Stulberg C.S., Swanborg N.K., Robinson A.R.;
RT   "Glucose-6-phosphate dehydrogenase isoenzymes in human cell cultures
RT   determined by sucrose-agar gel and cellulose acetate zymograms.";
RL   Proc. Soc. Exp. Biol. Med. 128:772-776(1968).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=6401685; DOI=10.1007/BF02617989;
RA   Halton D.M., Peterson W.D. Jr., Hukku B.;
RT   "Cell culture quality control by rapid isoenzymatic
RT   characterization.";
RL   In Vitro 19:16-24(1983).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=6988327; DOI=10.1007/BF02831503;
RA   O'Brien S.J., Shannon J.E., Gail M.H.;
RT   "A molecular approach to the identification and individualization of
RT   human and animal cells in culture: isozyme and allozyme genetic
RT   signatures.";
RL   In Vitro 16:119-135(1980).
//
RX   PubMed=10760816; DOI=10.1002/(SICI)1097-0215(20000501)86:3<307::AID-IJC2>3.0.CO;2-I;
RA   O-Charoenrat P., Rhys-Evans P.H., Modjtahedi H., Court W., Box G.,
RA   Eccles S.A.;
RT   "Overexpression of epidermal growth factor receptor in human head and
RT   neck squamous carcinoma cell lines correlates with matrix
RT   metalloproteinase-9 expression and in vitro invasion.";
RL   Int. J. Cancer 86:307-317(2000).
//
RX   PubMed=12124801; DOI=10.1002/ijc.10531;
RA   O-Charoenrat P., Rhys-Evans P.H., Eccles S.A.;
RT   "A synthetic matrix metalloproteinase inhibitor prevents squamous
RT   carcinoma cell proliferation by interfering with epidermal growth
RT   factor receptor autocrine loops.";
RL   Int. J. Cancer 100:527-533(2002).
//
RX   PubMed=15197768; DOI=10.1002/ijc.20228;
RA   O-Charoenrat P., Wongkajornsilp A., Rhys-Evans P.H., Eccles S.A.;
RT   "Signaling pathways required for matrix metalloproteinase-9 induction
RT   by betacellulin in head-and-neck squamous carcinoma cells.";
RL   Int. J. Cancer 111:174-183(2004).
//
RX   PubMed=18973137; DOI=10.1002/gcc.20626;
RA   Sugimoto T., Seki N., Shimizu S., Kikkawa N., Tsukada J., Shimada H.,
RA   Sasaki K., Hanazawa T., Okamoto Y., Hata A.;
RT   "The galanin signaling cascade is a candidate pathway regulating
RT   oncogenesis in human squamous cell carcinoma.";
RL   Genes Chromosomes Cancer 48:132-142(2009).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24201445; DOI=10.1101/gr.164806.113;
RA   Akagi K., Li J.-F., Broutian T.R., Padilla-Nash H.M., Xiao W.-H.,
RA   Jiang B., Rocco J.W., Teknos T.N., Kumar B., Wangsa D., He D., Ried T.,
RA   Symer D.E., Gillison M.L.;
RT   "Genome-wide analysis of HPV integration in human cancers reveals
RT   recurrent, focal genomic instability.";
RL   Genome Res. 24:185-199(2014).
//
RX   PubMed=25275298; DOI=10.18632/oncotarget.2417;
RA   Martin D., Abba M.C., Molinolo A.A., Vitale-Cross L., Wang Z.-Y.,
RA   Zaida M., Delic N.C., Samuels Y., Lyons J.G., Gutkind J.S.;
RT   "The head and neck cancer cell oncogenome: a platform for the
RT   development of precision molecular therapies.";
RL   Oncotarget 5:8906-8923(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26754630; DOI=10.1186/s13046-016-0284-4;
RA   Hyakusoku H., Sano D., Takahashi H., Hatano T., Isono Y., Shimada S.,
RA   Ito Y., Myers J.N., Oridate N.;
RT   "JunB promotes cell invasion, migration and distant metastasis of head
RT   and neck squamous cell carcinoma.";
RL   J. Exp. Clin. Cancer Res. 35:6.1-6.12(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=29423072; DOI=10.18632/oncotarget.23248;
RA   Steinbichler T.B., Abdelmoez A., Metzler V.M., Dejaco D.,
RA   Riechelmann H., Dudas J., Skvortsova I.-I.;
RT   "Epithelial-mesenchymal crosstalk induces radioresistance in HNSCC
RT   cells.";
RL   Oncotarget 9:3641-3652(2018).
//
RX   PubMed=30877674; DOI=10.1007/978-1-4939-9202-7_9;
RA   Kibble E.A., Sarkar-Tyson M., Coombs G.W., Kahler C.M.;
RT   "The Detroit 562 pharyngeal immortalized cell line model for the
RT   assessment of infectivity of pathogenic Neisseria sp.";
RL   Methods Mol. Biol. 1969:123-133(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//